DJIA 16,204.97 -211.61 -1.29%
NASDAQ 4,363.14 -146.42 -3.25%
S&P 500 1,880.05 -35.40 -1.85%
market minute promo

Sarepta Therapeutics (NASDAQ: SRPT)



company name or ticker

The Sarepta 12

BioMarin's FDA Panel: Revisiting Biotech's Biggest Battle

BioMarin's (BMRN) Kyndrisa Fails to Impress FDA Panel

Sarepta Therapeutics: Discretion Is the Better Part of Valor

Sarepta Therapeutics has been on an incredible bull run because of its experimental DMD therapy eteplirsen. Shareholders nevertheless need to consider taking one of two simple steps right now to protect themselves in case things reverse course in a hurry.

BioMarin's Duchenne Drug is Done, Sarepta Survives But Faces Challenge

BioMarin FDA Panel Live Blog

BioMarin Down on FDA's Briefing Document on Kyndrisa

BioMarin's DMD Drug Faces Obstacles Tomorrow

An FDA advisory committee will consider the company's therapy for Duchenne muscular dystrophy and its conclusions could impact competitor Sarepta Therapeutics.

Monday's ETF Movers: XBI, ILF

Sarepta Will Take Flight When Biomarin Taxis Off The Runway

See More Articles...